推荐产品
product name
CHIRAL-HSA 高效液相色谱柱, 5 μm particle size, L × I.D. 15 cm × 4 mm
材料
stainless steel column
agency
suitable for USP L79
產品線
CHIRALPAK®
包裝
pkg of 1 ea
製造商/商標名
CHIRALPAK®
參數
137 bar pressure (2000 psi)
20-30 °C temperature
40 °C max. temp.
技術
HPLC: suitable
長度 × 內徑
15 cm × 4 mm
基質
fully porous particle
基質活性組
human serum albumin phase
粒徑
5 μm
工作pH值
2-8
分離技術
chiral
正在寻找类似产品? 访问 产品对比指南
一般說明
CHIRALPAK HSA, which uses human serum albumin as the chiral selector, is highly selective for acidic racemates, preferably weak and strong acids, zwitterionic and non-protolytic (neutral) compounds. Phosphate buffers (normally 0.01-0.1M, pH 5-7) with addition of organic modifiers are used as mobile phases. Enantioselectivity and retention can be regulated by changing the mobile phase composition. However, the primary use of CHIRALPAK HSA is for fast drug/protein binding studies (1). To calculate the % protein binding, measure the retention time of an unretained compound (t0) and the compound of interest (tr) on the CHIRALPAK HSA column. Then use the capacity factor equation:
k = (tr - t0)/tr
to calculate the % protein binding (P):
P = 100k/(k+1)
Different types of mobile phases can be used. A mobile phase consisting of 6% 2-propanol in 20 mM potassium phosphate buffer, pH 7.0 gives data in good agreement with literature data. The mobile phase conditions should be chosen to suit the drugs to be tested, i.e., for high protein binding drugs a mobile phase with higher eluting strength might be needed in order to reduce retention times.
(1) Goodman, A.; Gilman, A.G. The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill: New York, 1996; pp 1712-1792.
k = (tr - t0)/tr
to calculate the % protein binding (P):
P = 100k/(k+1)
Different types of mobile phases can be used. A mobile phase consisting of 6% 2-propanol in 20 mM potassium phosphate buffer, pH 7.0 gives data in good agreement with literature data. The mobile phase conditions should be chosen to suit the drugs to be tested, i.e., for high protein binding drugs a mobile phase with higher eluting strength might be needed in order to reduce retention times.
(1) Goodman, A.; Gilman, A.G. The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill: New York, 1996; pp 1712-1792.
法律資訊
CHIRALPAK is a registered trademark of Daicel Corp.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门